Last reviewed · How we verify

Bevacizumab + Pemetrexed — Competitive Intelligence Brief

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + antifolate antimetabolite combination. Area: Oncology.

phase 3 Monoclonal antibody + antifolate antimetabolite combination VEGF (bevacizumab); folate-dependent enzymes (pemetrexed) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed) — PD Dr. med. Wolfgang Schuette. Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while pemetrexed inhibits folate-dependent enzymes to disrupt DNA synthesis and cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bevacizumab + Pemetrexed TARGET Bevacizumab + Pemetrexed PD Dr. med. Wolfgang Schuette phase 3 Monoclonal antibody + antifolate antimetabolite combination VEGF (bevacizumab); folate-dependent enzymes (pemetrexed)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + antifolate antimetabolite combination class)

  1. PD Dr. med. Wolfgang Schuette · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bevacizumab + Pemetrexed — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-pemetrexed. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: